Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer

Aranzazu Fernandez-Martinez, Ian E. Krop, David W. Hillman, Mei Yin Polley, Joel S. Parker, Lucas Huebner, Katherine A. Hoadley, Jonathan Shepherd, Sara Tolaney, N. Lynn Henry, Chau Dang, Lyndsay Harris, Donald Berry, Olwen Hahn, Clifford Hudis, Eric Winer, Ann Partridge, Charles M. Perou, Lisa A. Carey

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences